T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Public ClinicalTrials.gov record NCT06343311. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated lymphoma, primary and secondary central nervous system (CNS) lymphoma, and a wide range of high-grade B-cell lymphomas (HGBLs), as well as R/R large B-cell lymphoma (LBCL) patients ineligible for autologous transplant.
Study identification
- NCT ID
- NCT06343311
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 27 participants
Conditions and interventions
Conditions
- B-Cell Non-Hodgkin's Lymphoma (NHL)
- Lymphoma, Non-Hodgkins
- Lymphomas Non-Hodgkin's B-Cell
- Non-Hodgkin Lymphoma
- Non-Hodgkin's Lymphoma
- Large B-Cell Lymphoma
- Lymphoma, Non-Hodgkin's, Adult
- Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Lymphoma, Non-Hodgkin
- HIV Associated Lymphoma
- CNS Lymphoma
- High-grade B-cell Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 1, 2024 (Actual)
- Primary completion
- Jul 31, 2027 (Estimated)
- Completion
- Jul 31, 2028 (Estimated)
- Last update posted
- Oct 1, 2026
2024 – 2028
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Davis | Sacramento | California | 95817 | Recruiting |
| University Hospitals Seidman Cancer Center | Cleveland | Ohio | 44106 | Recruiting |
| Oregon Health and Sciences University | Portland | Oregon | 97239 | Recruiting |
| Baylor Scott & White Research Institute, Texas Oncology | Dallas | Texas | 75246 | Recruiting |
| Intermountain Health, Canyons Region, LDS Hospital | Salt Lake City | Utah | 84143 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06343311, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06343311 live on ClinicalTrials.gov.